CN107174599B

CN107174599B - Hemostatic, anti-inflammatory and stasis-removing medicine, preparation method thereof and hemostatic, anti-inflammatory and stasis-removing band-aid containing same

Info

Publication number: CN107174599B
Application number: CN201710465380.XA
Authority: CN
Inventors: 王代军
Original assignee: Hycorelle Health Technology Hubei Co ltd
Current assignee: Shandong kangle'er Biotechnology Co.,Ltd.
Priority date: 2017-06-19
Filing date: 2017-06-19
Publication date: 2020-11-10
Anticipated expiration: 2037-06-19
Also published as: CN107174599A

Abstract

The invention provides a hemostatic, anti-inflammatory and stasis-removing medicament, a preparation method thereof and a hemostatic, anti-inflammatory and stasis-removing band-aid containing the same. In the hemostatic, anti-inflammatory and stasis-removing medicament, the magnolia officinalis extract and the panax notoginseng extract are used as main medicinal substances in a compounding manner and are compounded with inorganic components such as citric acid, so that the hemostatic and anti-inflammatory effects on a wound surface can be effectively realized, and a good stasis-removing effect can be achieved. Meanwhile, the method has simple and convenient operation steps and few operation flows, and is suitable for large-scale production.

Description

Hemostatic, anti-inflammatory and stasis-removing medicine, preparation method thereof and hemostatic, anti-inflammatory and stasis-removing band-aid containing same

Technical Field

The invention relates to the field of medical dressings, in particular to a hemostatic, anti-inflammatory and desilting medicament, a preparation method thereof and a hemostatic, anti-inflammatory and desilting band-aid containing the same.

Background

The band-aid is an external dressing used for small-area openness, has the effects of stopping bleeding, protecting a wound surface, preventing infection, promoting healing and the like, is convenient to carry, has a simple use mode, and becomes a necessary surgical medicament for families.

However, although various wound dressings on the market can play a certain role in wound emergency, the functions of the wound dressings are mainly bandaging, isolation and protection. Because the existing band-aid with the attached medicament can not play an effective antibacterial and therapeutic role in practice, the wound surface treatment using the band-aid can cause further serious inflammation phenomena for infected wounds, and secondary inflammation diminishing and bandaging are needed for wounds with slightly larger wound surfaces, which is extremely unfavorable for the inflammation diminishing and recovery of the wounds. Furthermore, the wound surface is covered by the band-aid for a long time, the inflammation part of the wound can not be treated in time by medicines, and the wound is closed and bound by the band-aid for a long time, so that the normal blood circulation around the wound is blocked, particularly, the evaporation of local body heat of the wound is limited, the moisture around the wound is caused, the healing of the wound is not facilitated, the healing speed of the wound is slowed down, and extremely favorable survival and propagation conditions are possibly created for harmful bacteria, so that the further deterioration of the inflammation of the wound is caused, the wound is infected with suppuration, some unnecessary injuries are caused, and the health of a human body is influenced.

Therefore, it is a technical problem to be solved at present to develop a novel pharmaceutical preparation and load the pharmaceutical preparation on the woundplast, so as to effectively stop bleeding, diminish inflammation and remove blood stasis on the wound surface and further realize simple and effective treatment of the small wound surface.

In view of the above, the present invention is particularly proposed.

Disclosure of Invention

The first purpose of the invention is to provide a hemostatic, anti-inflammatory and desilting medicine, wherein the main drug effect substances of the hemostatic, anti-inflammatory and desilting medicine are magnolia officinalis extract and panax notoginseng extract, and the magnolia officinalis extract and the panax notoginseng extract are compounded with inorganic components such as citric acid, so that the hemostatic and anti-inflammatory effects on a wound surface can be effectively realized, and a good desilting effect can be achieved.

The second purpose of the invention is to provide a preparation method of the hemostatic, anti-inflammatory and stasis-removing medicine, which has simple and convenient operation steps and few operation flows and is suitable for large-scale production.

The third purpose of the invention is to provide the hemostatic, anti-inflammatory and desilting woundplast containing the hemostatic, anti-inflammatory and desilting medicine.

In order to achieve the above purpose of the present invention, the following technical solutions are adopted:

the medicine for stopping bleeding, diminishing inflammation and removing blood stasis is mainly prepared from the following components: magnolia bark extract, pseudo-ginseng extract, sodium citrate, potassium citrate, zinc citrate, potassium acetate, sodium chloride, sodium silicate and citric acid.

Optionally, in the hemostatic, anti-inflammatory and stasis-removing medicament, the dosage of each component is as follows in percentage by mass: 5-45% of magnolia officinalis extract, 3-40% of pseudo-ginseng extract, 30-70% of sodium citrate, 5-15% of potassium citrate, 0.1-3% of zinc citrate, 5-15% of potassium acetate, 3-12% of sodium chloride, 0-5% of sodium silicate and 0.1-10% of citric acid.

Optionally, in the hemostatic, anti-inflammatory and stasis-removing medicament, the dosage of each component is as follows in percentage by mass: 10-30% of magnolia officinalis extract, 5-30% of pseudo-ginseng extract, 40-60% of sodium citrate, 5-10% of potassium citrate, 0.1-1% of zinc citrate, 5-10% of potassium acetate, 5-10% of sodium chloride, 0-2% of sodium silicate and 0.2-5% of citric acid.

Meanwhile, the invention also provides a preparation method of the hemostatic, anti-inflammatory and stasis-removing medicine, which comprises the following steps: adding cortex Magnolia officinalis extract and Notoginseng radix extract into water, stirring and mixing to obtain solution a; adding sodium citrate, zinc citrate, potassium acetate, sodium chloride, sodium silicate and citric acid into water, and stirring for dissolving to obtain a solution b; then, the solution a is added into the solution b, and the mixture is stirred and evenly mixed to obtain the hemostatic, anti-inflammatory and stasis-removing medicine.

Optionally, in the preparation method of the medicine for stopping bleeding, diminishing inflammation and removing blood stasis, the preparation method of the magnolia bark extract comprises the following steps: pulverizing cortex Magnolia officinalis, extracting with ethanol, concentrating the extractive solution, adsorbing the obtained concentrated solution with resin, eluting with resin, and concentrating the obtained eluate to obtain cortex Magnolia officinalis extract.

Optionally, in the preparation method of the medicine for stopping bleeding, diminishing inflammation and removing blood stasis, the step of extracting the pulverized magnolia officinalis with alcohol comprises the following steps: crushing the mangnolia officinalis to 10-100 meshes, and then carrying out alcohol extraction on the mangnolia officinalis by using an ethanol solution with the concentration of 30-90%; preferably, the alcohol extraction times are 2-4.

Optionally, in the preparation method of the hemostatic, anti-inflammatory and stasis-removing medicament of the present invention, the preparation method of the notoginseng extract comprises the following steps: cleaning and drying pseudo-ginseng, crushing the pseudo-ginseng into particles, and then refluxing and extracting the particles with alcohol; filtering the extractive solution, adsorbing with resin, eluting with the resin, and concentrating the eluate to obtain Notoginseng radix extract.

Optionally, in the preparation method of the hemostatic, anti-inflammatory and stasis-removing medicine, the reflux alcohol extraction is performed by ethanol, and the concentration of the ethanol is 30-70%.

Similarly, the invention also provides a hemostatic, anti-inflammatory and desilting woundplast which comprises the hemostatic, anti-inflammatory and desilting medicament.

Optionally, the hemostatic, anti-inflammatory and dredging woundplast of the present invention comprises a wound pad, an adhesive backing and an isolation film; wherein, the wound protecting pad is impregnated with the hemostatic, anti-inflammatory and stasis-removing medicament.

Compared with the prior art, the invention has the beneficial effects that:

in the invention, the officinal components of the magnolia bark extract, the pseudo-ginseng extract and the like are compounded and used, and are compounded and used with inorganic components such as sodium citrate, potassium citrate, zinc citrate, potassium acetate, sodium chloride, sodium silicate, citric acid and the like, so that the medicament has good effects of stopping bleeding, diminishing inflammation and removing blood stasis;

meanwhile, the band-aid loaded with the medicine can be effectively attached to a wound surface, plays a role in protecting the wound surface, can effectively stop bleeding, diminish inflammation and remove blood stasis on the wound, promotes the wound to be effectively healed, and does not need secondary sterilization and binding.

Detailed Description

Embodiments of the present invention will be described in detail below with reference to examples, but it will be understood by those skilled in the art that the following examples are only illustrative of the present invention and should not be construed as limiting the scope of the present invention. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.

In view of the fact that the existing commercially available band-aid can not play an effective anti-inflammatory effect and the like, the phenomenon that the wound is further inflamed and worsened is often caused, the invention particularly provides a novel hemostatic, anti-inflammatory and stasis-removing medicine;

the medicine is prepared from the following components: magnolia bark extract, pseudo-ginseng extract, sodium citrate, potassium citrate, zinc citrate, potassium acetate, sodium chloride, sodium silicate and citric acid;

in a preferred embodiment of the present invention, the amounts of the raw material components in the medicament are referred to as follows:

5-45% of magnolia bark extract, such as but not limited to 10, 15, 20, 25, 30, 35, or 40%; 3-40% of the notoginseng extract, for example, but not limited to, 5, 10, 15, 20, 25, 30, or 35%; 30-70% of sodium citrate, for example, but not limited to, 40, 50, 60, or 70% and the like; 5-15% of potassium citrate, for example, but not limited to, 8, 10, or 12% and the like; zinc citrate 0.1-3%, for example, but not limited to, 0.5, 2, or 2%; 5-15% of potassium acetate, for example, but not limited to, 8, 10, or 12%; 3-12% of sodium chloride, for example, but not limited to, 5, 8, or 10%; 0 to 5% of sodium silicate, for example, but not limited to, 1, 2, 3, or 4%; and 0.1 to 10% of citric acid, for example, but not limited to, 0.2, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, or 9%.

The effective components of the plant extract are compounded with effective inorganic components with functions of permeation, inflammation diminishing and the like, so that the medicine has good effects of stopping bleeding and diminishing inflammation and can play a good role of removing blood stasis.

More preferably, in the medicament of the present invention, the amounts of the raw material components are as follows: 10-30% of magnolia officinalis extract, 5-30% of pseudo-ginseng extract, 40-60% of sodium citrate, 5-10% of potassium citrate, 0.1-1% of zinc citrate, 5-10% of potassium acetate, 5-10% of sodium chloride, 0-2% of sodium silicate and 0.2-5% of citric acid.

Meanwhile, the preparation method of the hemostatic, anti-inflammatory and desilting medicine is simple and convenient, does not need any large-scale equipment, and can refer to the following specific steps:

(a) adding cortex Magnolia officinalis extract and Notoginseng radix extract into water, stirring and mixing to obtain solution a;

preferably, the preparation method of the magnolia bark extract can refer to the following steps: pulverizing the mangnolia officinalis, preferably to 10-100 meshes; then adding 10-15 times of 30-90% ethanol solution for ethanol extraction, and performing reflux extraction for 2-4 times, wherein each time of extraction is 1-2 hours; concentrating the obtained extract, adsorbing by using macroporous resin, eluting by using 50-90% ethanol solution, collecting eluent, and concentrating to obtain a magnolia officinalis extract;

preferably, the preparation method of the panax notoginseng extract can refer to the following steps: cleaning and drying pseudo-ginseng, crushing the pseudo-ginseng into particles, and then refluxing and extracting the particles with an ethanol solution, wherein the concentration of the ethanol solution is preferably 30-70%, and the dosage of the ethanol solution is 10-15 times of that of the pseudo-ginseng particles; the number of times of alcohol extraction is preferably 2-3, and the time of each extraction is preferably 1-2 h; filtering the obtained extracting solution, adsorbing by using macroporous resin, and then eluting the resin after adsorption, wherein the preferred eluent is 50-90% ethanol solution; concentrating the eluate to obtain Notoginseng radix extract;

(b) adding sodium citrate, zinc citrate, potassium acetate, sodium chloride, sodium silicate and citric acid into water, and stirring for dissolving to obtain a solution b;

then, the solution a is added into the solution b, and the mixture is stirred and evenly mixed to obtain the hemostatic, anti-inflammatory and stasis-removing medicine.

Furthermore, the invention also provides a hemostatic, anti-inflammatory and desilting woundplast, which comprises a wound protection pad, an adhesive backing and an isolation film, wherein the wound protection pad is impregnated with the hemostatic, anti-inflammatory and desilting medicine;

furthermore, the wound protection pad is arranged on the adhesive surface layer of the adhesive backing, and the isolation film covers the wound protection pad and the adhesive surface layer to play a role in isolating and preventing adhesion.

Preferably, the adhesive backing is a backing coated with hypoallergenic medical pressure-sensitive adhesive on one side, and more preferably, the material of the backing can be PU film (for waterproof function), elastic cloth (for compression hemostasis function), or non-woven fabric or perforated PE (for ventilation effect).

Meanwhile, the preparation method of the band-aid can refer to the following steps: soaking a water-absorbing material into the hemostatic, anti-inflammatory and stasis-removing medicine, soaking for 10-20 min, then putting into an oven, drying and rolling;

cutting the water-absorbing material to a proper size (namely the wound protection pad), then adhering the cut and molded adhesive surface layer of the adhesive backing, then attaching the isolating film to the adhesive surface layer, and covering the water-absorbing material to obtain the adhesive bandage of the invention;

further, the obtained band-aid can be packaged, and each band-aid can be well sealed.

Example 1

According to the mass percentage, 5 percent of magnolia officinalis extract, 40 percent of pseudo-ginseng extract, 30 percent of sodium citrate, 5 percent of potassium citrate, 3 percent of zinc citrate, 10 percent of potassium acetate, 5 percent of sodium chloride, 1 percent of sodium silicate and 1 percent of citric acid are respectively weighed and added with proper amount of raw materials;

the preparation method of the magnolia bark extract comprises the following steps: pulverizing the mangnolia officinalis, preferably to 10-100 meshes; then adding 10 times of 30-90% ethanol solution for ethanol extraction, and performing reflux extraction for 3 times, wherein each extraction is performed for 1 hour; concentrating the obtained extract, adsorbing with macroporous resin, eluting with 75% ethanol solution, collecting eluate, and concentrating to obtain cortex Magnolia officinalis extract;

the preparation method of the pseudo-ginseng extract comprises the following steps: cleaning and drying pseudo-ginseng, crushing the pseudo-ginseng into particles, and then refluxing and extracting the particles for 3 times by 10-15 times of 30-70% ethanol solution, wherein the extraction time is 2 hours each time; filtering the obtained extract, adsorbing by macroporous resin, and eluting the adsorbed resin by 80% ethanol solution; concentrating the eluate to obtain Notoginseng radix extract;

adding cortex Magnolia officinalis extract and Notoginseng radix extract into water, stirring and mixing to obtain solution a; adding sodium citrate, zinc citrate, potassium acetate, sodium chloride, sodium silicate and citric acid into water, and stirring for dissolving to obtain a solution b;

and then adding the solution a into the solution b, and uniformly stirring to obtain the hemostatic, anti-inflammatory and stasis-removing medicament of the embodiment 1.

Example 2

40% of magnolia officinalis extract, 3% of pseudo-ginseng extract, 30% of sodium citrate, 12% of potassium citrate, 0.1% of zinc citrate, 5% of potassium acetate, 8% of sodium chloride, 0.9% of sodium silicate and 1% of citric acid in percentage by mass; weighing appropriate amount of each raw material respectively, and making the total amount of the weighed raw materials the same as that in example 1;

wherein, the preparation methods of magnolia bark extract and notoginseng extract in example 2 are the same as those in example 1;

then, the hemostatic, anti-inflammatory and stasis-removing agent of example 2 was prepared by the method described in reference example 1, and the total amount of water used in the method of example 2 was the same as that of example 1.

Example 3

According to the mass percentage, 10 percent of magnolia officinalis extract, 30 percent of pseudo-ginseng extract, 40 percent of sodium citrate, 8 percent of potassium citrate, 1 percent of zinc citrate, 5 percent of potassium acetate, 5 percent of sodium chloride, 0.8 percent of sodium silicate and 0.2 percent of citric acid are respectively weighed, and the total amount of the weighed raw materials is the same as that of the raw materials in the example 1;

wherein, the preparation methods of magnolia bark extract and notoginseng extract in example 3 are the same as those in example 1;

then, the hemostatic, anti-inflammatory and stasis-removing agent of example 3 was prepared as described in reference to example 1, and the total amount of water used in the method of example 3 was the same as that of example 1.

Example 4

According to the mass fraction, 30% of magnolia officinalis extract, 5% of pseudo-ginseng extract, 40% of sodium citrate, 5% of potassium citrate, 1% of zinc citrate, 8% of potassium acetate, 6% of sodium chloride, 1% of sodium silicate and 4% of citric acid are respectively weighed, and the total amount of the weighed raw materials is the same as that in example 1;

wherein, the preparation methods of magnolia bark extract and notoginseng extract in example 4 are the same as those in example 1;

then, the hemostatic, anti-inflammatory and stasis-removing agent of example 4 was prepared as described in reference to example 1, and the total amount of water used in the method of example 4 was the same as that of example 1.

Example 5

According to the mass percentage, 20 percent of magnolia officinalis extract, 20 percent of pseudo-ginseng extract, 40 percent of sodium citrate, 8 percent of potassium citrate, 1 percent of zinc citrate, 5 percent of potassium acetate, 5 percent of sodium chloride, 0.8 percent of sodium silicate and 0.2 percent of citric acid are respectively weighed, and the total amount of the weighed raw materials is the same as that of the raw materials in the example 1;

wherein, the preparation methods of magnolia bark extract and notoginseng radix extract in example 5 are the same as those in example 1;

then, the hemostatic, anti-inflammatory and stasis-removing agent of example 5 was prepared by the method described in reference example 1, and the total amount of water used in the method of example 5 was the same as that of example 1.

Comparative example 1

According to the mass percentage, 40 percent of magnolia officinalis extract, 40 percent of sodium citrate, 8 percent of potassium citrate, 1 percent of zinc citrate, 5 percent of potassium acetate, 5 percent of sodium chloride, 0.8 percent of sodium silicate and 0.2 percent of citric acid are respectively weighed, and the total amount of the weighed raw materials is the same as that of the example 1;

wherein, the preparation methods of magnolia bark extract and notoginseng radix extract in comparative example 1 are the same as in example 1;

then, the drug of comparative example 1 was prepared by referring to the method described in example 1, and the total amount of water used in the method of comparative example 1 was the same as in example 1.

Comparative example 2

According to the mass percentage, 40 percent of pseudo-ginseng extract, 40 percent of sodium citrate, 8 percent of potassium citrate, 1 percent of zinc citrate, 5 percent of potassium acetate, 5 percent of sodium chloride, 0.8 percent of sodium silicate and 0.2 percent of citric acid are respectively weighed, and the total amount of the weighed raw materials is the same as that of the example 1;

wherein, the preparation methods of magnolia bark extract and notoginseng radix extract in comparative example 2 are the same as in example 1;

then, the drug of comparative example 2 was prepared by referring to the method described in example 1, and the total amount of water used in the method of comparative example 2 was the same as that of example 1.

Comparative example 3

Respectively weighing 50% of magnolia bark extract and 50% of pseudo-ginseng extract according to the mass percentage, and ensuring that the total mass of the weighed raw materials is the same as the total mass of the magnolia bark extract and the pseudo-ginseng extract in the example 5;

then, the weighed raw materials were added to water to be dissolved, to obtain the drug of comparative example 3, and the amount of water used in comparative example 3 was the same as the total amount of water used in example 1.

Experimental example 1

(1) Experiment of antibacterial Properties

Taking a proper amount of sterilized water-absorbing non-woven fabrics with the diameter of 5mm, respectively placing the sterilized water-absorbing non-woven fabrics into the medicines of examples 1-5 and comparative examples 1-3, and soaking for 20 min to obtain impregnated non-woven fabrics;

the cell concentration was 1X 10⁵Evenly smearing cfu/mL bacterial liquid on an agar plate, placing impregnated non-woven fabrics on the bacterial liquid after the bacterial liquid is air-dried, culturing for 24 hours at 37 ℃, determining the size of a bacteriostatic ring, repeating the experiment for 3 times, and calculating the average value, wherein the results are shown in the following table:

therefore, the medicament has good antibacterial and anti-inflammatory properties, and has good antibacterial properties by compounding the magnolia officinalis extract and the pseudo-ginseng extract and compounding with inorganic components such as citric acid and the like.

(2) Hemostatic effect

Taking a proper amount of sterilized water-absorbing non-woven fabrics with the diameter of 10mm, respectively placing the sterilized water-absorbing non-woven fabrics into the medicines of examples 1-5 and comparative examples 1-3, and soaking for 20 min to obtain impregnated non-woven fabrics;

taking 45 healthy rabbits with the weight of 2.3-2.8 Kg, randomly dividing the rabbits into 9 groups, namely an example 1-5 group, a comparative example 1-3 group and a blank control group;

depilating the back of the rabbit by using a depilatory, and after 24 hours, carrying out intravenous injection anesthesia on the rabbit by using 1% sodium pentobarbital 30mg/Kg of ear margin; scratching the depilated skin by using a scalpel, wherein the length of the wound is about 1cm, and the degree of obvious bleeding is taken; immediately covering each group of impregnated non-woven fabrics on the wound after the wound surface is filled with blood, and lightly pressing to make the non-woven fabrics attached to the wound;

observing the bleeding condition of the wound every 20s, slightly pressing the non-woven fabric by using the filter paper strip until the blood does not seep out and the filter paper strip is not stained with the blood, recording the required time as the bleeding time, repeating the experiment for 3 times, and calculating the average time, wherein the results are shown in the following table:

therefore, the medicine can play a role in quickly stopping bleeding, and the permeation speed of the drug-effect substances is improved by compounding with inorganic components such as citric acid and the like, so that the hemostatic effect is further improved.

While particular embodiments of the present invention have been illustrated and described, it would be obvious that various other changes and modifications can be made without departing from the spirit and scope of the invention. It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this invention.

Claims

1. The hemostatic, anti-inflammatory and stasis-removing medicine is characterized by mainly comprising the following components: magnolia bark extract, pseudo-ginseng extract, sodium citrate, potassium citrate, zinc citrate, potassium acetate, sodium chloride, sodium silicate and citric acid.

2. The hemostatic, anti-inflammatory and stasis-removing medicine as claimed in claim 1, which is characterized in that the dosage of each component is as follows according to mass percentage:

5-45% of magnolia officinalis extract, 3-40% of pseudo-ginseng extract, 30-70% of sodium citrate, 5-15% of potassium citrate, 0.1-3% of zinc citrate, 5-15% of potassium acetate, 3-12% of sodium chloride, 0-5% of sodium silicate and 0.1-10% of citric acid.

3. The hemostatic, anti-inflammatory and stasis-removing medicine as claimed in claim 2, characterized in that the dosage of each component is as follows by mass percent:

10-30% of magnolia officinalis extract, 5-30% of pseudo-ginseng extract, 40-60% of sodium citrate, 5-10% of potassium citrate, 0.1-1% of zinc citrate, 5-10% of potassium acetate, 5-10% of sodium chloride, 0-2% of sodium silicate and 0.2-5% of citric acid.

4. A process for the preparation of a medicament as claimed in any one of claims 1 to 3, wherein the process comprises the steps of:

adding cortex Magnolia officinalis extract and Notoginseng radix extract into water, stirring and mixing to obtain solution a;

adding sodium citrate, zinc citrate, potassium acetate, sodium chloride, sodium silicate and citric acid into water, and stirring for dissolving to obtain a solution b;

5. The method as set forth in claim 4, wherein the Magnolia bark extract is prepared by the method comprising the steps of:

pulverizing cortex Magnolia officinalis, extracting with ethanol, concentrating the extractive solution, adsorbing the obtained concentrated solution with resin, eluting with resin, and concentrating the obtained eluate to obtain cortex Magnolia officinalis extract.

6. The preparation method of claim 5, wherein the alcohol extraction of the pulverized magnolia bark comprises the following steps: pulverizing the mangnolia officinalis to 10-100 meshes, and then extracting with ethanol solution with the concentration of 30-90%.

7. The preparation method according to claim 6, wherein the number of times of alcohol extraction is 2-4.

8. The method of claim 4, wherein the Panax notoginseng extract is prepared by the steps of: cleaning and drying pseudo-ginseng, crushing the pseudo-ginseng into particles, and then refluxing and extracting the particles with alcohol; filtering the extractive solution, adsorbing with resin, eluting with the resin, and concentrating the eluate to obtain Notoginseng radix extract.

9. The preparation method according to claim 8, wherein the reflux alcohol extraction is performed by using ethanol, and the concentration of the ethanol is 30-70%.

10. A hemostatic, anti-inflammatory and stasis-removing woundplast, which is characterized by comprising the hemostatic, anti-inflammatory and stasis-removing medicament as claimed in any one of claims 1 to 3.

11. The hemostatic, anti-inflammatory, and stasis-removing adhesive bandage of claim 10, which comprises a wound pad, an adhesive backing, and a barrier film;

wherein the wound pad is impregnated with the hemostatic, anti-inflammatory, and stasis-removing medicament of any one of claims 1-3.